Pharmacoeconomic Spotlight on Varenicline as an Aid to Smoking Cessation†
- 1 September 2010
- journal article
- review article
- Published by Springer Science and Business Media LLC in CNS Drugs
- Vol. 24 (9), 797-800
- https://doi.org/10.2165/11204710-000000000-00000
Abstract
Varenicline (Chantix, Champix) is an orally administered alpha4beta2 nicotinic acetylcholine receptor partial agonist that is indicated as an aid to smoking cessation. Varenicline was an effective aid to smoking cessation and was generally well tolerated in clinical trials, although more data are needed regarding the potential for neuropsychiatric events. The costs associated with varenicline are offset by direct savings associated with the reduction in smoking-related diseases. Indeed, despite their limitations, available pharmacoeconomic analyses from numerous countries support the use of varenicline for 12 or 24 weeks as a cost-effective treatment relative to other smoking cessation therapies in smokers who wish to quit smoking. For example, in modelled cost-effectiveness analyses conducted from a healthcare payer perspective, 12 weeks' treatment with varenicline consistently dominated bupropion sustained release and nicotine replacement therapy, and was dominant over, or considered cost effective relative to, unaided cessation, brief counselling or nortriptyline, with regard to the incremental costs per quality-adjusted life-year or life-year gained.Keywords
This publication has 29 references indexed in Scilit:
- VareniclinePharmacoEconomics, 2010
- Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokersCurrent Medical Research and Opinion, 2010
- Cost Effectiveness of Varenicline in Belgium, Compared with Bupropion, Nicotine Replacement Therapy, Brief Counselling and Unaided Smoking CessationClinical Drug Investigation, 2009
- Cost-effectiveness of varenicline compared with nicotine patches for smoking cessation—results from four European countriesEuropean Journal of Public Health, 2009
- Varenicline versus transdermal nicotine patch for smoking cessation: results from a randomised open-label trialThorax, 2008
- Análisis coste-efectividad de vareniclina (Champix®) en el tratamiento del tabaquismo en EspañaAnales de Medicina Interna, 2008
- Cost-Utility Analysis of Varenicline versus Existing Smoking Cessation Strategies using the BENESCO Simulation ModelPharmacoEconomics, 2008
- Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the NetherlandsCurrent Medical Research and Opinion, 2007
- Regional, disease specific patterns of smoking-attributable mortality in 2000Tobacco Control, 2004
- The problem of tobacco smokingBMJ, 2004